Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16659190 | 0.88 | CYP3A4 (0.44) | OPRM1CYP3A4TMEM97OPRD1PRSS1 | |
| SCHEMBL320602 | 0.87 | TMEM97 (0.40) | OPRM1CYP3A4TMEM97OPRD1KCNH2 | |
| SCHEMBL3742950 | 0.81 | HTR2C (0.46) | — | |
| SCHEMBL12084866 | 0.81 | HTR2C (0.46) | DRD2 | |
| SCHEMBL15780787 | 0.81 | MMP12 (0.41) | OPRM1OPRD1KCNH2PRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL2800247 | 0.79 | HTR2C (0.44) | — | |
| SCHEMBL13740056 | 0.78 | OPRD1 (0.39) | OPRD1KCNH2PRSS1PRSS2PRSS3 | |
| SCHEMBL320709 | 0.78 | TMEM97 (0.38) | OPRM1CYP3A4TMEM97OPRD1KCNH2 | |
| SCHEMBL13738033 | 0.78 | PRSS1 (0.47) | OPRM1OPRD1KCNH2PRSS1PRSS2 | |
| SCHEMBL29941779 | 0.77 | PRSS1 (0.49) | PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427598-B2 | Spiro-cyclic amine derivatives as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2022-08-30 | — | — | US | disclosed |
| US-11427598-B2 | Spiro-cyclic amine derivatives as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2022-08-30 | — | — | US | disclosed |
| US-20210130364-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2021-05-06 | — | — | US | disclosed |
| US-20210130364-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2021-05-06 | — | — | US | disclosed |
| US-10807991-B2 | Spiro-cyclic amine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2020-10-20 | — | — | US | disclosed |
| US-10807991-B2 | Spiro-cyclic amine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2020-10-20 | — | — | US | disclosed |
| US-20190218227-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-07-18 | — | — | US | disclosed |
| US-20190218227-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-07-18 | — | — | US | disclosed |
| US-10179791-B2 | Spiro-cyclic amine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2019-01-15 | — | — | US | disclosed |
| US-10179791-B2 | Spiro-cyclic amine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2019-01-15 | — | — | US | disclosed |
| US-20160340363-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-11-24 | — | — | US | disclosed |
| US-20160340363-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-11-24 | — | — | US | disclosed |
| EP-2590955-B1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2016-10-12 | — | — | EP | disclosed |
| EP-2590955-B1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2016-10-12 | — | — | EP | disclosed |
| US-20130196998-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-01 | — | — | US | disclosed |
| US-20130196998-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-01 | — | — | US | disclosed |
| US-20130196998-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-01 | — | — | US | disclosed |
| EP-2590955-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004378-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004378-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427598-B2 | Spiro-cyclic amine derivatives as S1P modulators | S1PR1, S1PR3, S1PR2 | OPRM1 670/4885CYP3A4 2725/4885TMEM97 620/4885 |
| US-20130196998-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | OPRM1 349/4885CYP3A4 1499/4885TMEM97 1592/4885 |
| US-20190218227-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | OPRM1 646/4885CYP3A4 2603/4885TMEM97 630/4885 |
| US-10807991-B2 | Spiro-cyclic amine derivatives as S1P modulators | S1PR1, S1PR3, S1PR2 | OPRM1 670/4885CYP3A4 2725/4885TMEM97 620/4885 |
| US-20160340363-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | OPRM1 646/4885CYP3A4 2603/4885TMEM97 630/4885 |
| US-10179791-B2 | Spiro-cyclic amine derivatives as S1P modulators | S1PR3, S1PR1, S1PR2 | OPRM1 349/4885CYP3A4 1499/4885TMEM97 1592/4885 |
| US-20210130364-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | OPRM1 670/4885CYP3A4 2725/4885TMEM97 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.